Clinical Trial Detail

NCT ID NCT02577406
Title An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Celgene
Indications

bone marrow cancer

acute myeloid leukemia

Therapies

Azacitidine

Cytarabine

Enasidenib

Age Groups: senior

Additional content available in CKB BOOST